Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19
- 3 January 2021
- journal article
- review article
- Published by Springer Nature in Current Microbiology
- Vol. 78 (2) , 435-448
Abstract
The newly identified 2019 novel coronavirus (SARS-CoV-2) has become a public health concern globally posing a significant threat to human health and economy and creating an unprecedented crisis in all spheres of the global life. Emergence of new genotypes of SARS-CoV during the last few years has pointed out the limited efficacy of available vaccines and antivirals, constraining the global response to the COVID-19 outburst to largely monitoring/containment. There is high priority for treatment regimes and new potential therapeutic and vaccine strategies. Several candidates have shown promising outcomes in various in vitro and in vivo models. In addition, clinical trials are in progress to test conceivable therapies showing promising outcomes in various in vivo studies. Unfortunately, very little information is available in the scientific scope which offers details to the diverse strategies being targeted to fight the pandemic, particularly with respect to the molecular targets. This review article summarizes and highlights the ongoing advances and approaches that are being carried out across the globe in designing vaccines and novel therapeutics, with particular reference to the previous knowledge gained from other viral infections like with the earlier SARS and MERS-CoV. A detailed knowledge may pave the way to combat this pandemic COVID-19 as well as prevent similar deadly epidemics in future.Keywords
This publication has 87 references indexed in Scilit:
- Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly NeutralizingPLOS ONE, 2012
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Mechanism of Inhibition of Enveloped Virus Membrane Fusion by the Antiviral Drug ArbidolPLOS ONE, 2011
- Ritonavir-boosted protease inhibitors in HIV therapyAnnals of Medicine, 2011
- Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse modelAntiviral Research, 2011
- Severe Acute Respiratory Syndrome Coronavirus nsp1 Suppresses Host Gene Expression, Including That of Type I Interferon, in Infected CellsJournal of Virology, 2008
- Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The NetherlandsJournal of Infection, 2005
- Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main ProteasesPLOS Biology, 2005
- Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994–1999 report)The Journal of Laryngology & Otology, 2004
- The Use of Interferon-α in Virus InfectionsDrugs, 1991